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ABSTRACT
Motor neuron disease (MND) is a progressive degenerative disorder of the motor neurons, resulting in progressive limb, 
bulbar and respiratory muscle weakness. No definitive disease modifying treatment is available at this time. The 
mainstay of management remains multidisciplinary care, which has shown to improve quality of life, prevents 
complications and may also increase life span. 
In this review, different medical specialties necessary to offer complete multidisciplinary care are discussed. 
Symptomatic management of individual symptoms commonly experienced by patients with MND is elaborated on. 
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R E V I E W  A R T I C L E
INTRODUCTION: Despite recent advances in the 
availability of approved drugs for the treatment of motor 
neuron disease (MND)/Amyotrophic lateral sclerosis 
(ALS), symptomatic treatment remains the main stay 
for the management of these patients.(1) MND can 
present with asymmetric or symmetric limb weakness 
or can have its onset in the bulbar muscles with speech 
and swallowing difficulties. This is a progressive 
degenerative disorder of motor neurons residing in the 
motor cortex, brain stem and anterior horns. Presenting 
symptoms and progression of the disease varies 
amongst individuals, possibly influenced by genetic and 
environmental factors.  The median survival, from 
symptom onset to death, ranges from 20 to 48 
months. (2) Only 10% patients with ALS live over 10 
years of disease duration. (2) Older age and bulbar 
symptoms at onset are poor prognostic factors. (2) 
Overtime it has become clear that MND is not just a 
disorder of motor neuron degeneration but involves 
other brain regions too. For example, patients suffer 
from behavioral and cognitive issues at some point 
during their illness as a result of degeneration of the 
frontal lobes.(3) Therefore management of MND needs 
a holistic multi-disciplinary approach. 
Multidisciplinary care of patients with MND has shown 
to improve quality of life, decrease complications and 
hospitalizations, prolong survival and decrease 
mortality.(1, 4-6)  This review aims to describe the 
components necessary for successful multidisciplinary 
management of patients with MND and the evidence 
behind timely supportive interventions.
 
MULTIDISCIPLINARY CLINICS
Successful multidisciplinary care of MND/ALS requires 
specialized clinics where a patient is systematically 
evaluated by multiple specialists on the same day. A 
multidisciplinary clinic (MDC) decreases the burden on 
patients and care givers who would otherwise be 
compelled to go to different specialists, at different 
locations and times. A MDC provides co-ordinated care 
and typically includes assessment and management by 
multiple team members. (7, 8) At the end of the clinic, 
ideally, the team discusses individual specialty 
recommendations and comes up with a health care 
plan for the patient. Each team member has defined 
goals: (7, 8)
1. Neurologist: responsible for diagnosis, breaking the 
news, clinical monitoring, prescribing medications, 
co-ordination with other health care personnel, 
discussing scientific evidence, answering questions and 
provide information about enrollment in clinical trials. It 
is useful to assess the patient based on a scale such as 
the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
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SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
5 2P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
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should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
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should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
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COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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the ALS functional rating scale- revised (ALSFRS-R) to 
document the disease course.
2. Speech and language therapist: evaluates oral 
motor and swallowing function, gives advice for 
oropharyngeal exercises, is responsible for early 
detection of dysphagia and works with the patients on 
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric 
intake and provides the patient and family with a dietary 
plan to follow. They work in close association with the 
speech therapist for appropriate dietary advice 
according to the swallowing status. Maintaining BMI is 
important as rapid weight loss is considered a poor 
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical 
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association 
with the PT and assess home safety and performance 
of activities of daily living. PT and OT together assess 
and advice for the need of assistive devices to help with 
daily activities. 
6. Neuropsychologist/psychiatrist: responsible for early 
detection of mood, behavioral and cognitive changes, 
helps with end of life decisions and provides emotional 
support for the patient and family. 
7. The nurse manager and social worker works as a 
liaison between the patient and health care team. 
The team works in close contact with a palliative care 
specialist, gastroenterologist and pulmonologist for 
timely intervention with percutaneous gastrostomy 
(PEG) and/or non-invasive ventilation (NIV) respectively. 
Multidisciplinary care in motor neuron disease (MND)
SYMPTOMATIC MANAGEMENT
Besides disease modifying agents, specifically Riluzole 
(9)and possibly Edaravone(10), the mainstay of 
management for all MND patients remains optimal care 
for evolving symptoms. The aim is to improve quality of 
life of the patient and family, prevent complications and 
decrease hospitalizations.
 
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles 
also become progressively weak in MND. Inspiration is 
an active process, requiring contraction of intercostal, 
diaphragmatic and accessory muscles to generate a 
negative intrathoracic pressure and allow air inflow. 
(11) Upper motor neurons further control and modify 
the pattern of breathing. As a result of progressive 
weakness of respiratory muscles and loss of upper 
motor neurons, patients experience symptoms such as 
shortness of breath on exertion, orthopnoea, 
non-refreshing sleep, morning headaches and loss of 
appetite. Even asymptomatic patients can have 
respiratory muscle weakness (12), making regular 
screening of these patients all the more important, 
even in early stages of the disease. Neuromuscular 
respiratory failure is the most common cause of death 
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by 
Bourke et al (13), non-invasive ventilations ( NIV) 
significantly improved quality of life and survival in 
patients with non-bulbar ALS. Similar survival benefits 
were not seen in patients with bulbar symptoms; 
however there was improvement in sleep related 
symptoms in this group. (13) A recent Cochrane review 
(14) corroborated these findings with some suggestion 
that patients who have not yet developed respiratory 
symptoms or have mild respiratory muscle involvement 
may have a higher survival benefit and improvement in 
quality of life, however this is still under 
investigation.(14) NIV works by improving oxygenation, 
decreasing work of breathing and fatigue, improving 
lung compliance and reversing hypercapnia thereby 
improving central respiratory drive. (11) NIV should be 
offered to patients in a timely manner, before they 
develop frank respiratory failure in order to obtain the 
maximum quality of life and prolong survival. 
Assessment of respiratory function through symptoms, 
oxygen saturation, forced vital capacity (FVC) and 
maximal inspiratory pressure (MIP) is recommended at 
the time of diagnosis and at every 3 months follow up. 
Nocturnal oximetry should be considered in doubtful 
cases. The predicted FVC and a decline in FVC is the 
most important predictor of survival. (19)  Ideally FVC 
should be recorded both sitting and supine and a 25% 
drop in FVC in the supine position strongly suggests 
diaphragmatic weakness.(1) Patients who full fill the 
criteria of neuromuscular respiratory failure i.e., those 
with orthopnea, MIP < -60cm, FVC <50% predicted or 
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level 
positive airway pressure (BIPAP). Compliance and 
tolerance to NIV can be an issue. Individuals with 
bulbar onset MND may experience difficulty in 
tolerating BIPAP due to pooling of secretions and weak 
cough, which in turn can result in a lot of anxiety.(15) 
Those with cognitive decline or frontotemporal 
dementia may show low adherence to the use of 
NIV.(15) Therefore a mutual decision needs to be made 
after extensive counseling of the patient and family. 
Intensive educational training has shown to improve 
compliance and adaptation to NIV.(16) Transtracheal 
invasive ventilation is offered to patients who wish to 
stay on long term ventilatory support, however it is 
resource intensive.
Diaphragmatic pacing in ALS patients was shown to 
decrease survival and is not recommended for MND 
patients at this time while further studies on this are 
ongoing. (17) 
Along with respiratory decline, a weak cough and the 
consequent difficulty in clearing respiratory secretions 
is a common cause of lower respiratory tract infections. 
These patients need intensive respiratory therapy with 
suctioning and clearance of secretions. Mucolytic 
agents such as carbocisteine may be used.
HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva 
in the mouth, which can be socially embarrassing for 
the patient and can also increase the risk of aspiration 
pneumonia. Oral medications are tried as first line 
therapy. Options include amitriptyline, benztropine, 
trihexyphenidyl, scopolamine, atropine drops or 
glycopyrolate.(7, 18) If medications are unable to 
control the hypersialorrhea or side effects limit their 
use, then botox injections in the parotid and/or 
submandibular gland or low dose radiation to the 
salivary glands can be considered.(7, 18, 19)
NUTRITION
Rapid decline in weight and BMI (<18.5) is associated 
with progression of disease and decrease in survival.(1, 
20, 21)  Reasons for inadequate oral intake are 
multifactorial and include dysphagia, weakness of 
upper limbs making patients dependent on others for 
feeding, depression or cognitive decline and increase in 
the resting metabolism.(1, 20) BMI and the nutritional 
plan need to be documented and discussed on every 
visit. 
Initial intervention for dysphagia can include altering 
consistency and texture of food and additional 
supplements to improve caloric intake. Ultimately, to 
maintain BMI, a gastrostomy is needed. A swallowing 
assessment performed at every visit by the speech 
therapist can help guide the clinician in timing 
discussions with the patient and family for gastrostomy 
placement. Feeding via gastrostomy aims to decrease 
the risk of aspiration, reduce the need for 
hospitalization and maintain body weight. (1, 22) The 
ideal time for gastrostomy placement is not known, 
however should be considered when there is more than 
10% weight loss (23). The ProGas trial (22) was the 
first multicenter cohort study to indicate the benefits of 
early gastrostomy. Patients who had more than 10% 
loss of weight prior to PEG placement, from the time of 
diagnosis to the procedure, had shorter survival and 
were less likely to regain that weight. The risk of 
complications during the gastrostomy procedure is low 
if the FVC is ≥ 38% of predicted and the PaCo2 is 
normal.(24) Different methods of gastrostomy ( 
percutaneous endoscopic, radiologically inserted or 
per-oral image guided) are not superior to each other 
and the decision is made based on the respiratory 
status of the patient, ability to lie flat and physician 
preference. (22, 25) 
There have been numerous studies with insufficient 
evidence for the use of vitamin supplements including 
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme 
Q10 and creatine monohydrate.(1, 18) Similarly, the 
benefits of high carbohydrate, high protein or high fat 
diets are controversial.(18, 20) The nutritionist should 
make a diet plan based on individual needs and offer 
high energy supplements early if necessary. 
PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic, 
involuntary, excessive crying, laughter, yawning that is 
seen in up to 50% of MND/ALS patients.(26) This 
significantly impairs quality of life and effects social 
functioning. Antidepressants such as tricyclic 
antidepressants (amitriptyline) and serotonin re-uptake 
inhibitors (citalopram) are frequently used. (7, 20) 
Pioro et al reported a combination of dextromethorphan 
(DM) 30mg and quinidine (Q) 10mg reduced the 
frequency and severity of laughing and crying behaviors 
compared to either drug alone.(27)A fixed dose 
combination of DM/Q (30mg/10mg) is recommended 
for treatment of PBA. (7)
COMMUNICATION
 
The speech and language therapist guides the patient 
and family in exercises and to use tools to help with 
communication. Based on availability, assistive devices 
are prescribed. These include word, alphabet, sound 
and visual command cards, typing devices, speaker 
phones, sound synthesizers or personal digital 
assistance (PDA). 
ASSISTIVE DEVICES AND EQUIPMENT
Regular assessment by the physiotherapists and 
occupational therapists will address the need for aids 
for mobility and activities of daily living (ADL). The home 
environment needs to be assessed for safety and 
adapted according to individual person’s needs. For 
example, adjustments in bathrooms with arm rails by 
the toilet, elevated toilet seat, shower seat and shower 
bars. Devices most often used for mobility include a 
cane, walker, wheelchair and ankle brace for 
ambulation.(28) For severely weak patients a sliding 
transfer board at home is recommended. ADLs can be 
made easy by simple interventions such as modified 
eating utensils with thick handles for better grip, wrist 
braces, slip-on shoes, and electric seating controls for 
a beds or wheelchairs. (28) Although the cost of some 
of this equipment is high, there are no studies on cost 
effectiveness as yet. In the long run, complications of 
falls and immobility can be avoided, decreasing 
hospitalization and improving quality of life.
CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug 
for cramps in MND patients, but quinine, gabapentin 
and vitamin E are widely used. (7, 29) Spasticity is 
treated by encouraging physical therapy and use of 
drugs used for increased tone in other central nervous 
disorders such as baclofen, tizanidine and 
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS 
patients, mostly behavioral variant of  frontotemporal 
dementia.(30) Cognitive deficits in fluency, language, 
social cognition, executive functions and verbal 
memory have been documented. (31) The role of the 
neuropsychiatrist/psychologist in the MDC is to assess 
all MND patients using neuropsychological testing. 
Early intervention and counseling for cognitive and 
behavioral changes will improve quality of life and 
decrease care giver burden. 
Depression and/or anxiety may result from uncertainty 
or delay in diagnosis, prognosis of the disease, as part 
of the cognitive changes or due to drug side effects. All 
patients are screened for mood disorders and treated 
accordingly. No drugs are indicated for mood disorders 
specifically in MND; however they can be prescribed 
based on their side effect profile, which may even help 
other symptoms e.g hypersialorrhea and PBA.
INSOMNIA AND FATIGUE
Insomnia and fatigue become common complaints in 
MND especially as the disease progresses. Multiple 
aspects of the disease already discussed contribute to 
sleep disturbances. The earliest sign of respiratory 
muscle weakness may just be insomnia that is related 
to nocturnal hypoventilation.(15) Other factors 
affecting sleep include depression, anxiety, immobility, 
muscle cramps and restless legs syndrome.(15) 
Decrease in restful sleep, in turn, can aggravate other 
symptoms like depression, anxiety, cramps and 
cognitive decline. Clinically, insomnia is treated with 
medications such as zolpidem and amitriptyline while 
identifying the primary cause and its treatment. 
Modafinil may be used for excessive day time 
somnolence or fatigue.(20)
DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in 
patients with ALS and was approved by the FDA in 
1995. It’s mechanism of action is not clearly known but 
it has shown to modulate the effects of glutamate, both 
by inhibiting its release and modulating post synaptic 
glutamate receptor signaling. Riluzole is also reported 
to have neuroprotective effects. (32) It slows 
progression of disease and lengthens survival by at 
least 3 months, initially shown in two large placebo 
controlled trials.(9, 33) It is safe to use at a dose of 
100mg daily, with the most common side effects of 
raised liver enzymes, asthenia, dizziness and 
gastrointestinal discomfort.(33) Riluzole must be 
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical 
scavenger, Edaravone, which was first approved in 
Japan in 2015 for treatment of ALS, followed by FDA 
approval in 2017.However, it is not yet approved in 
Europe, and there are widespread conflicting opinions 
amongst neuromuscular specialists about its benefits 
and accelerated approval. Edaravone is delivered by 
intravenous infusions in cycles consisting of daily 
dosing for 2 weeks followed by a 2-week drug-free 
period .The initial trial conducted in Japan had a short 
6 months duration of intervention with very constrictive 
inclusion criteria. These criteria included age 20 to 75 
years, a Japan ALS Severity Classification of grade 1 or 
2 (no to mild disability), scores of at least 2 points on 
all 12 items of the ALS Functional Rating Scale-Revised 
(ALSFRS-R), forced vital capacity of 80% or more, 
definite or probable ALS according to the revised El 
Escorial criteria and disease duration of 2 years or 
less.(10) The proportion of patients with bulbar onset 
ALS was less and those with score of 3 or less on 
ALSFRS-R items for dyspnea, orthopnea, or respiratory 
insufficiency were excluded. The results showed a 
slowing in the decline of the ALSFRS-R score by 33% 
over the 6 months period. Although the positive 
outcome is remarkable, this needs further trials, with 
inclusion of a wider spectrum of MND patients, longer 
duration of treatment and follow up for long term 
benefits and side effects.
New treatments are under investigation. Ongoing trials 
are looking at the effect of stem cell and gene therapies 
targeting Superoxide dismutase 1 (SOD 1) and C9orf2 
repeat expansions seen in some cases of ALS.(34) 
CONCLUSION
In a disease where patients and families easily give up 
hope due to lack of definitive treatment, it is necessary 
for the treating physician to explain the importance and 
impact of multidisciplinary care. MDC remains the 
standard of care for management of MND to improve 
the quality of life, minimize hospitalizations and 
improve health outcomes.(35) Palliative care and end 
of life care is also an integral part of the 
multidisciplinary care. The MDC team will assist the 
patient and family with an end of life care plan to avoid 
anxiety and emotional decisions, when the time comes. 
In our experience, MDC makes acceptance of the 
disease easier both for patients and their caregivers.  It 
not only serves to address every aspect of the disease 
but at times can also serve as a support group for 
patients and families attending the clinic. 
Establishing and running a MDC is expensive and often 
the cost is supported by individuals or philanthropic 
organizations (35), however this is the only proven way 
to improve the quality of life of  patients with MND  and 
can also serve as resource for research.  As the search 
for a disease modifying treatment continues, 
committing resources and personnel to MDCs for the 
management of motor neuron disease should remain a 
priority for tertiary care neurological centers.
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